Market Closed -
Nasdaq
01:30:00 25/06/2024 am IST
|
5-day change
|
1st Jan Change
|
53.9
USD
|
+0.71%
|
|
+2.12%
|
-35.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
627.7
|
1,471
|
3,823
|
4,336
|
8,186
|
6,263
|
-
|
-
|
Enterprise Value (EV)
1 |
531.8
|
1,142
|
3,495
|
4,163
|
8,179
|
5,799
|
5,789
|
5,852
|
P/E ratio
|
-5.03
x
|
-10.5
x
|
-16.3
x
|
-10.6
x
|
-15.3
x
|
-12.1
x
|
-12.2
x
|
-19.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.4
x
|
26.3
x
|
54.3
x
|
45.8
x
|
1,087
x
|
195
x
|
85.9
x
|
16.3
x
|
EV / Revenue
|
19.8
x
|
20.5
x
|
49.6
x
|
44
x
|
1,086
x
|
180
x
|
79.4
x
|
15.2
x
|
EV / EBITDA
|
-5.45
x
|
-12.4
x
|
-19
x
|
-13.1
x
|
-16.9
x
|
-12.9
x
|
-13.1
x
|
-30.4
x
|
EV / FCF
|
-
|
-
|
-18.3
x
|
-13.4
x
|
-19.7
x
|
-15.3
x
|
-11.8
x
|
147
x
|
FCF Yield
|
-
|
-
|
-5.48%
|
-7.47%
|
-5.08%
|
-6.55%
|
-8.45%
|
0.68%
|
Price to Book
|
-57.4
x
|
13
x
|
15.8
x
|
-40.3
x
|
-22
x
|
-22.5
x
|
-23.7
x
|
-140
x
|
Nbr of stocks (in thousands)
|
59,161
|
70,779
|
83,883
|
94,631
|
98,054
|
1,16,204
|
-
|
-
|
Reference price
2 |
10.61
|
20.78
|
45.58
|
45.82
|
83.49
|
53.90
|
53.90
|
53.90
|
Announcement Date
|
03/03/20
|
25/02/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
26.87
|
55.83
|
70.43
|
94.59
|
7.53
|
32.14
|
72.94
|
383.8
|
EBITDA
1 |
-97.57
|
-92.11
|
-184
|
-318.4
|
-484.3
|
-450.3
|
-442.5
|
-192.4
|
EBIT
1 |
-98.87
|
-93.94
|
-186.3
|
-324.2
|
-496.2
|
-465.6
|
-482.1
|
-272.9
|
Operating Margin
|
-367.97%
|
-168.27%
|
-264.54%
|
-342.75%
|
-6,589.71%
|
-1,448.63%
|
-660.95%
|
-71.12%
|
Earnings before Tax (EBT)
1 |
-121.7
|
-127.3
|
-215.3
|
-389
|
-526.2
|
-487.5
|
-513.2
|
-339.5
|
Net income
1 |
-121.7
|
-127.3
|
-215.3
|
-389
|
-526.2
|
-490.1
|
-494.1
|
-317.7
|
Net margin
|
-452.93%
|
-228%
|
-305.72%
|
-411.21%
|
-6,988.63%
|
-1,524.81%
|
-677.38%
|
-82.78%
|
EPS
2 |
-2.110
|
-1.970
|
-2.800
|
-4.330
|
-5.450
|
-4.438
|
-4.417
|
-2.733
|
Free Cash Flow
1 |
-
|
-
|
-191.4
|
-310.9
|
-415.7
|
-379.7
|
-489.3
|
39.82
|
FCF margin
|
-
|
-
|
-271.76%
|
-328.64%
|
-5,521.24%
|
-1,181.54%
|
-670.8%
|
10.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/20
|
25/02/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
7.42
|
55.6
|
1.148
|
88.97
|
2.515
|
1.957
|
4.613
|
0.867
|
0.378
|
1.672
|
0.835
|
20.96
|
2.164
|
4.278
|
1.171
|
2.333
|
EBITDA
1 |
-
|
-20.97
|
-76.52
|
-9.467
|
-107
|
-125.4
|
-122.6
|
-120.2
|
-120.4
|
-121.1
|
-
|
-103
|
-113
|
-102.8
|
-
|
-
|
EBIT
1 |
-62.72
|
-21.7
|
-77.86
|
-10.87
|
-108.4
|
-127
|
-124.5
|
-122
|
-122.3
|
-127.4
|
-126.2
|
-109.5
|
-115.1
|
-114.2
|
-119.9
|
-118.5
|
Operating Margin
|
-845.28%
|
-39.04%
|
-6,781.97%
|
-12.22%
|
-4,311.77%
|
-6,491.06%
|
-2,698.31%
|
-14,077.16%
|
-32,345.24%
|
-7,620.69%
|
-15,117.96%
|
-522.28%
|
-5,320.02%
|
-2,668.8%
|
-10,239.79%
|
-5,077.79%
|
Earnings before Tax (EBT)
1 |
-80.19
|
-30.57
|
-89.44
|
-19.82
|
-142.3
|
-137.4
|
-131.3
|
-128.6
|
-129.4
|
-136.9
|
-135.6
|
-112.4
|
-118.7
|
-122.5
|
-113.9
|
-118.2
|
Net income
1 |
-80.19
|
-30.57
|
-89.44
|
-19.82
|
-142.3
|
-137.4
|
-131.3
|
-128.6
|
-129.4
|
-136.9
|
-135.6
|
-112.5
|
-119
|
-121
|
-111.2
|
-115.4
|
Net margin
|
-1,080.73%
|
-54.98%
|
-7,791.38%
|
-22.28%
|
-5,658.45%
|
-7,019.93%
|
-2,846.07%
|
-14,837.02%
|
-34,238.62%
|
-8,187.56%
|
-16,244.67%
|
-536.72%
|
-5,500.58%
|
-2,827.89%
|
-9,493.28%
|
-4,947.42%
|
EPS
2 |
-
|
-0.3600
|
-1.050
|
-0.2300
|
-1.520
|
-1.450
|
-1.380
|
-1.340
|
-1.350
|
-1.380
|
-1.330
|
-0.9422
|
-1.102
|
-1.054
|
-1.138
|
-1.063
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/08/20
|
24/02/22
|
04/05/22
|
04/08/22
|
03/11/22
|
01/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
27/02/24
|
08/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
95.9
|
328
|
329
|
173
|
7.45
|
464
|
474
|
412
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-191
|
-311
|
-416
|
-380
|
-489
|
39.8
|
ROE (net income / shareholders' equity)
|
-
|
-112%
|
-121%
|
-572%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-31.3%
|
-41.9%
|
-57.2%
|
-49.9%
|
-58.5%
|
-51.4%
|
Assets
1 |
-
|
-
|
687.6
|
928
|
919.5
|
982.1
|
844.6
|
618.1
|
Book Value Per Share
2 |
-0.1800
|
1.600
|
2.880
|
-1.140
|
-3.800
|
-2.400
|
-2.280
|
-0.3900
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-3.330
|
-4.290
|
-2.680
|
-1.380
|
-
|
Capex
1 |
-
|
-
|
48.9
|
11.3
|
1.42
|
3.53
|
8.24
|
27.4
|
Capex / Sales
|
-
|
-
|
69.39%
|
11.98%
|
18.8%
|
10.98%
|
11.3%
|
7.13%
|
Announcement Date
|
03/03/20
|
25/02/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
53.9
USD Average target price
82.65
USD Spread / Average Target +53.33% Consensus |
1st Jan change
|
Capi.
|
---|
| -35.44% | 626.34Cr | | +16.73% | 12TCr | | +21.13% | 11TCr | | +21.16% | 2.59TCr | | -17.94% | 2.09TCr | | -16.24% | 1.65TCr | | -11.76% | 1.68TCr | | -44.45% | 1.56TCr | | +69.92% | 1.55TCr | | +1.41% | 1.34TCr |
Bio Therapeutic Drugs
|